CGEN
Compugen Ltd.
CGEN has slightly lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over CGEN overall, supported by stronger fundamentals and stronger modeled upside.
CGEN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Strong |
CGEN's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
CGEN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 5.5x | $2.09 | -1.3% |
| Current | 5.7x | $2.12 | — |
| Fair | 6.5x | $2.48 | +17% |
| Expensive | 8x | $3.04 | +43% |
Historical ranges are pointers, not guarantees.
CGEN's PE is 5.7x, but its earnings don't support one, so it isn't a reliable read right now.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over CGEN in the historical PE scenario, which offers more potential upside but is not a forecast.
CGEN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Decline | |
| -- | |
| Limited | |
| Low |
Analysts expect CGEN's losses to grow, with revenue declining. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
CGEN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $0.38 | +$0.59 |
| Q1 2026 | $0.37 | +$0.53 |
| Q4 2025 | $0.37 | +$0.53 |
| Q3 2025 | -$0.30 | -1600% |
| Q2 2025 | -$0.21 | -$0.11 |
| Q1 2025 | -$0.16 | +$0.03 |
| Q4 2024 | -$0.16 | +$0.06 |
| Q3 2024 | $0.02 | +$0.39 |
CGEN has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
CGEN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $2.6M | +107% |
| Q1 2026 | $2.2M | -4.7% |
| Q4 2025 | $67.3M | +4477% |
| Q3 2025 | $1.9M | -89% |
| Q2 2025 | $1.3M | -81% |
| Q1 2025 | $2.3M | -11% |
| Q4 2024 | $1.5M | -96% |
| Q4 2023 | $33.5M | +346% |
CGEN's revenue is growing: $3M last quarter, up 107% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -340% | +331 points |
| Q1 2026 | -414% | -47 points |
| Q4 2025 | 83% | +592 points |
| Q3 2025 | -417% | -444 points |
| Q2 2025 | -671% | -620 points |
| Q1 2025 | -368% | -36 points |
| Q4 2024 | -509% | -563 points |
| Q3 2024 | 26% | N/A |
CGEN's operating margin was −340% last quarter, up 331 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over CGEN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over CGEN on profitability, with a higher operating margin.
CGEN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $0 | $0 |
| Q1 2026 | $0 | $0 |
| Q4 2025 | $0 | $0 |
| Q3 2025 | $0 | $0 |
| Q2 2025 | $0 | $0 |
| Q1 2025 | $0 | $0 |
| Q4 2024 | $0 | $0 |
| Q3 2024 | $0 | $0 |
CGEN's free cash flow was $0 over the past year, against $0 the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over CGEN on cash flow, with more consistent year-over-year improvement.
CGEN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +84.5K shares |
| 1 year | +1.2% | +1.1M shares |
| 3 years | +8.6% | +7.5M shares |
| 5 years | +13% | +10.8M shares |
| Available history | +45% | +29.2M shares |
CGEN has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
CGEN hasn't bought back shares in the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
CGEN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -0.2x | Net Cash |
| Q1 2026 | -0.3x | Net Cash |
| Q4 2025 | -2.5x | Net Cash |
| Q3 2024 | -0.3x | Net Cash |
CGEN has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over CGEN on leverage, with a lower net debt burden relative to earnings.
CGEN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.8 | Neutral |
| Stochastic | 14.3 | Oversold |
CGEN's weekly RSI is 46 (neutral) and its Stochastic is 14 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
CGEN PE vs Healthcare Sector
| Metric | CGEN | Sector median | Relative |
|---|---|---|---|
| PE | 5.7x | 26x | 78% below |
| PE % | 21 | 29 | 8 pts below |
CGEN has the edge over OSCR on valuation relative to its sector.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
CGEN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.10 | 1% above |
| 20 week MA | $2.30 | 7.8% below |
| 50 week MA | $2.20 | 3.6% below |
| 100 week MA | $1.92 | 10% above |
| 200 week MA | $1.69 | 25% above |
CGEN's trend is mixed: it's above three of its five weekly moving averages, and 25% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over CGEN on trend strength, trading above more of its moving averages.
CGEN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $6.16 | $13.1 | +113% |
| 2021 | $13.1 | $4.56 | -65% |
| 2022 | $4.56 | $0.76 | -83% |
| 2023 | $0.76 | $1.98 | +161% |
| 2024 | $1.98 | $1.57 | -21% |
| 2025 | $1.57 | $1.54 | -1.9% |
| 2026 YTD | $1.54 | $2.12 | +38% |
CGEN's yearly returns have swung widely, from +161% in 2023 to −83% in 2022. It's up 38% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over CGEN on returns for 2026, with the stronger performance.